Macrophage

Agendia Announces New Data Assessing the Immune Active State in HR+/HER2- Early-Stage Breast Cancer at 2024 ASCO

Retrieved on: 
пятница, мая 31, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Patient, MP, MammaPrint, Transcriptome, University, Antigen presentation, Breast cancer, HR, MD, APC, Neoplasm, PD-1, Macrophage, Biomarker, ASCO, Division, Gene, Associate, B cell, Woman, Society, Classification, Immunotherapy, Kurt Cobain, PD-L1, Checkmate, SWOG, Medical imaging

Agendia®, Inc. today announced it will present new data characterizing the immune biology of MammaPrint High Risk tumors in an oral session at the 2024 Annual American Society of Clinical Oncology (ASCO) Meeting , taking place in Chicago, IL.

Key Points: 
  • Agendia®, Inc. today announced it will present new data characterizing the immune biology of MammaPrint High Risk tumors in an oral session at the 2024 Annual American Society of Clinical Oncology (ASCO) Meeting , taking place in Chicago, IL.
  • characterizes the underlying immune biology that mediates immune therapy response in early stage hormone receptor-positive (HR+), Human Epidermal Growth Factor Receptor negative (HER2-) breast cancer, categorized as MammaPrint High Risk 2 (MP H2) in patients enrolled in the prospective, observational FLEX Study ( NCT03053193 ).
  • The data from this study suggests that early stage HR+HER2- High-2 tumors might benefit from the addition of immunotherapy to their chemotherapy treatment regimens.
  • “There is a great need for biomarkers beyond PD-L1 and tumor mutational burden that may predict clinical benefit from immunotherapy-based treatments.

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

Retrieved on: 
вторник, мая 28, 2024
Apolipoprotein AI, LDL, Juntendo University, SAFETY, ATP, Patient, Cardiovascular disease, Fats, Oxysterol, Human, Lipid metabolism, EAS, CERP, ABCG1, Liver, ABCA1, Messenger, SAE, MD, Congress, NAFLD, Qi, Macrophage, DMSO, Abstract, Tokyo Stock Exchange, Leukemia, LXR, HDL, Cell, Apo, ABCA, Research, Liposome, Cholesterol, PKA, Code, Vaccine

As of 25 April 2024, 33 patients were enrolled, 19 patients were randomized, 14 patients completed the study.

Key Points: 
  • As of 25 April 2024, 33 patients were enrolled, 19 patients were randomized, 14 patients completed the study.
  • Three subjects reported serious adverse events (SAE) and were all considered “Unlikely related” or “Unrelated“ to study drug.
  • Objectives of this study are to evaluate the effects of MN-001 and its major active metabolite MN-002 on cholesterol efflux capacity in THP-1 *1macrophages.
  • ABCG1 also effluxes cholesterol to low-density lipoproteins (LDL), liposomes and cyclodextrin and it exports sphingomyelin, phosphatidylcholine and oxysterols to HDL and albumin.

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

Retrieved on: 
пятница, мая 24, 2024
Radiation therapy, Peking Union Medical College, EP4, Esophageal cancer, Medicine, ANL, Clinical trial, Tumor microenvironment, Trial of the century, Safety, Neoadjuvant therapy, Macrophage, ASCO, Hospital, Society, CRT, Annual general meeting, Pharmaceutical industry

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.

Key Points: 
  • SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.
  • AN0025 is a selective EP4 inhibitor that demonstrates antitumor activity by modulating the function of macrophages and immunosuppressive myeloid cells in tumor microenvironment.
  • The combination of AN0025 with CRT as neoadjuvant therapy has shown synergistic antitumor efficacy in locally advanced rectal cancer in a prior clinical trial (NCT03152370).
  • The AN0025S0104 study is a single-arm, open-label, multicenter, Phase Ib study comprising a dose escalation phase followed by an expansion phase, aimed at evaluating the safety, tolerability, and feasibility of AN0025 plus dCRT for unresectable locally advanced or locally recurrent EC or esophagogastric junction cancer.

Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

Retrieved on: 
четверг, мая 16, 2024
Faron Pharmaceuticals, Patient, MDS, European Patent Convention, Myelocyte, AIM, European, SME, Invention, Research, Macrophage, Myelodysplastic syndrome, Majesty of the Seas, Nasdaq First North, Immunotherapy, Standard of care, Quality of life, SOC, Pharmaceutical industry

Dr. Markku Jalkanen, co-founder, Board member and former CEO of Faron, and Dr. Sirpa Jalkanen, co-founder and member of Faron’s Scientific Advisory Board, have been nominated in recognition of their research developing Faron’s wholly owned precision cancer immunotherapy candidate, bexmarilimab.

Key Points: 
  • Dr. Markku Jalkanen, co-founder, Board member and former CEO of Faron, and Dr. Sirpa Jalkanen, co-founder and member of Faron’s Scientific Advisory Board, have been nominated in recognition of their research developing Faron’s wholly owned precision cancer immunotherapy candidate, bexmarilimab.
  • In addition, every year, the public can vote for their favorite inventor: the Popular Prize goes to the shortlisted inventor with the most votes.
  • The winners in each category, and the winner of the Popular Prize, will be announced at the online award ceremony on 9 July 2024.
  • The continued progress of our ambitious bexmarilimab development program and the exceptional data we are seeing in the ongoing Phase I/II BEXMAB trial, reaffirms our belief in the potential of bexmarilimab to change the treatment paradigm.

New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Retrieved on: 
четверг, мая 16, 2024
Doctor of Philosophy, Toxicity, Asos, Therapy, LNC, Small RNA, Macrophage, Cell, Poster, Lecture, Vaccine

BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.

Key Points: 
  • BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.
  • The poster, “Intracellular Delivery of Small Oligonucleotides with Lipid Nanocrystals (LNCs): in vitro studies,” was presented by Hui Liu, PhD, Chief Technology Officer of Matinas, and is available here .
  • The poster discusses in vitro studies demonstrating the avid uptake of LNC formulations of various cytokine-targeted small oligonucleotides in murine macrophages, with up to 70% gene knockdown observed for each targeted cytokine.
  • These characteristics make LNCs a highly promising oral drug delivery platform for future applications requiring oral delivery of small oligonucleotides.”

aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference

Retrieved on: 
среда, мая 15, 2024
Patient, Phenotype, Systemic scleroderma, Myelocyte, ATyr Pharma, Autoimmunity, Scleroderma, American Thoracic Society, SAN, Conference, NRP2, Pathology, Sarcoidosis, Tissue, Macrophage, Scar, ATS, Monocyte, Poster, Fibrosis, ILD, Inflammation, Small RNA, Neuropilin, Pharmaceutical industry

The poster will be available on the aTyr website once presented.

Key Points: 
  • The poster will be available on the aTyr website once presented.
  • These findings suggest that efzofitimod may have broad therapeutic potential in diseases where myeloid cells play a central role in pathology, including ILD.
  • Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis.
  • These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.

AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)

Retrieved on: 
четверг, мая 23, 2024
Biotechnology, FDA, Pharmaceutical, Health, Patient, RWE, Bortezomib, Science, Heart failure, Prevalence, Diagnosis, ISA, Disease, Epidemiology, EMR, Senior, Death, Alexion, Ionis, Macrophage, Incidence, Polyneuropathy, Cardiomyopathy, Phagocytosis, ATTR, Poster, Inborn errors of metabolism, Outline, AstraZeneca, Daratumumab, Amyloid, Pharmaceutical industry

AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26–30, 2024.

Key Points: 
  • AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26–30, 2024.
  • Sarah Walters, Vice President, US Cardiovascular, Renal & Metabolic Diseases, AstraZeneca, said: “AstraZeneca is dedicated to advancing the science and improving the lives of patients that are impacted by this devastating disease.
  • A retrospective chart analysis from the US EMR TriNetX database will report outcomes in AL amyloidosis patients with renal involvement receiving bortezomib or daratumumab.
  • A comprehensive list of AstraZeneca key abstracts to be presented at the 2024 International Symposium on Amyloidosis includes7:

Pheast Unveils First Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor

Retrieved on: 
понедельник, мая 13, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Therapy, Neoplasm, Cancer, Macrophage, Protein engineering, CD24, Protein Sciences, TNBC, Monoclonal antibody, Ovary, Vaccine

Pheast Therapeutics (“Pheast”), a biotech developing novel macrophage checkpoint therapies to defy cancer, today announced the first presentation of preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells.

Key Points: 
  • Pheast Therapeutics (“Pheast”), a biotech developing novel macrophage checkpoint therapies to defy cancer, today announced the first presentation of preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells.
  • “Pheast’s lead drug candidate, PHST001, is an exceptionally well-engineered, well-expressed antibody against an exciting new target, CD24,” said Roy Maute, Ph.D., Cofounder and CEO, Pheast Therapeutics.
  • Pheast has engineered PHST001 to bind recombinant CD24 and cell surface CD24 with high affinity and specificity and to block Siglec-10 binding.
  • Pheast scientists have demonstrated that blocking CD24 with PHST001 induces macrophage phagocytosis of multiple cancer subtypes in vitro, and have shown potent efficacy for PHST001 in vivo.

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

Retrieved on: 
четверг, мая 9, 2024
Sale, TNF, Phase, DSM-IV codes, Patient, MUC4, CD47, Pacific Rim, CTLA4, LAG3, Research, Tumor microenvironment, Conference, Downregulation and upregulation, Disease, Exercise, Chemistry, SRC, Macrophage, BOCA, TIGIT, Treatment-resistant depression, Neuroinflammation, Neoplasm, Deficit spending, TME, Pharmaceutical industry

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update.
  • INB03 cancer platform – two posters were presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
  • Financial Results for the First Quarter Ended March 31, 2024:
    Net loss attributable to common stockholders for the quarter ended March 31, 2024 was approximately $11.0 million, compared to approximately $6.5 million during the quarter ended March 31, 2023.
  • Please ask for the INmune Bio First Quarter Conference Call when reaching an operator.

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
четверг, мая 9, 2024
MIBC, FDA, Cancer, Urology, Fast Track, Necrosis, SPA, Safety, General counsel, Research, Recurrence, Growth, Light, Bladder cancer, Immunogenic cell death, Incidence, Patient, Enrollment, Compass, Macrophage, NMIBC, Neoplasm, Annual general meeting, Damage-associated molecular pattern, ARVO, Pharmaceutical industry

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.

Key Points: 
  • Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024
    BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.
  • “Throughout the first quarter of 2024, the Company made significant progress across our ocular and urologic oncology therapeutic area programs,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.
  • As of March 31, 2024, Aura had cash and cash equivalents and marketable securities totaling $202.9 million.
  • General and administrative expenses include $1.4 million and $1.1 million of stock-based compensation for the three months ended March 31, 2024 and 2023, respectively.